Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ho-Jung Choe

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|November 10, 2025
Pt(IV) Prodrugs Bearing Sunitinib-Derived Ligands Display Exceptional Anticancer Activity against Renal Cell Carcinoma When Compared to Conventional Platinum ChemotherapyDarren F Beirne, Jemma Arakelyan, Matteo Forner, et al.
Journal of the American Chemical Society|February 24, 2025
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma TumorsMeng Rui Chang, Egor M Matnurov, Chengnan Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2025
Modulating the microbiome as an approach to anticancer drug developmentJemma Arakelyan, Ho-Jung Choe, Chengnan Wu, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|November 10, 2025
Pt(IV) Prodrugs Bearing Sunitinib-Derived Ligands Display Exceptional Anticancer Activity against Renal Cell Carcinoma When Compared to Conventional Platinum ChemotherapyDarren F Beirne, Jemma Arakelyan, Matteo Forner, et al.
Journal of the American Chemical Society|February 24, 2025
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma TumorsMeng Rui Chang, Egor M Matnurov, Chengnan Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2025
Modulating the microbiome as an approach to anticancer drug developmentJemma Arakelyan, Ho-Jung Choe, Chengnan Wu, et al.
Pageof 1